Drug Trial Radar · NCT06400511
A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment
Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
477
Actual
Start
Apr 22, 2024
Primary completion
Sep 9, 2025
Study completion Oct 15, 2025
Sponsor
- Lead sponsor
- Famy Life Sciences, a Viatris CompanyIndustry
- Sponsor type
- Industry
- First posted
- May 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to determine the efficacy and safety of Pimecrolimus 0.3% (MR-139) Ophthalmic Ointment.
Conditions
- Blepharitis
Interventions
Pimecrolimus 0.3% Ophthalmic OintmentDrug
Pimecrolimus 0.3% Ophthalmic Ointment will be applied twice a day to both eyelid margins.
Placebo Ophthalmic OintmentDrug
Placebo will be applied twice a day to both eyelid margins.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of Study DrugTime frame: 6 weeks
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
Clinical Investigative Site
Pheonix, Arizona
Clinical Investigator Site
Garden Grove, California
Clinical Investigator Site
Glendale, California
Clinical Investigator Site
Inglewood, California
Clinical Investigator Site
Newport Beach, California
Clinical Investigator Site
Petaluma, California
Clinical Investigator Site
Rancho Cordova, California
Clinical Investigator Site
Aurora, Colorado
Clinical Investigator Site
Crystal River, Florida
Clinical Investigator Site
Largo, Florida
Clinical Investigator Site
Tampa, Florida
Clinical Investigator Site
Atlanta, Georgia
Clinical Investigator Site
Morrow, Georgia
Clinical Investigator Site
Pittsburg, Kansas
Clinical Investigator Site
Louisville, Kentucky
Clinical Investigator Site
Havre de Grace, Maryland
Clinical Investigator Site
Medina, Minnesota
Clinical Investigator Site
Kansas City, Missouri
Investigative Site
St Louis, Missouri
Clinical Investigator Site
Washington, Missouri
Clinical Investigator Site
Garner, North Carolina
Clinical Investigator Site
Cincinnati, Ohio
Clinical Investigator Site
Cranberry Township, Pennsylvania
Clinical Investigator Site
Smyrna, Tennessee
Clinical Investigator Site
Austin, Texas
Clinical Investigator Site
Lakeway, Texas
Clinical Investigator Site
San Antonio, Texas
Clinical Investigator Site
Clinton, Utah
Clinical Investigator Site
Lynchburg, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.